MedTrace Logo

Remifentanil and Desflurane Inhalational Anesthesia in Bariatric Surgeries

NCT03219788 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2017-07-18

No results posted yet for this study

Summary

The number of obese and overweighted persons doubled since 1980. They are 600 million in 2014 all over the world. Obesity results in anatomical, physiological and pharmacological changes which represent a challenge for every anesthetist. Difficult airway increases by 30% with obesity and so awake extubation are the preferred technique. Coughing can be alleviated by opioid receptors which play a role in the cough reflex. Remifentanil may be useful as an ultra-short acting opioid and its effect swiftly and predictably disappears after cessation. An emergence cough is attenuated by remifentanil administered via continuous infusion (TCI), and the expected effective effect-site concentrations investigated have ranged from 1.5 to 2.5 ng.ml/L.

Conditions

  • Anesthesia Emergence

Interventions

DRUG

Normal Saline

All the patient will be anesthetized using a standard anesthetic technique. One ml normal saline will be given

DRUG

Remifentanil 0.1 ug/kg

All the patient will be anesthetized using a standard anesthetic technique. One ml normal saline contains 0.1 ug/kg Remifentanil will be given

DRUG

Remifentanil 0.2 ug/kg

All the patient will be anesthetized using a standard anesthetic technique. One ml normal saline contains 0.2 ug/kg Remifentanil will be given

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Mohamed S Ali, MD · Associate profossor of anesthesiology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-20
Primary Completion
2017-11-01
Completion
2017-11-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03219788 on ClinicalTrials.gov